Karen Lewis Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Karen Lewis is Chief People Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 46,387 shares of APLS, which is worth approximately $1.27 Million. The most recent transaction as insider was on Jan 30, 2024, when has been sold 883 shares (Common Stock) at a price of $65.53 per share, resulting in proceeds of $57,862. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.4K

0% 3M change

11.77% 12M change

Total Value Held $1.27 Million

Karen Lewis Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 30 2024	SELL Open market or private sale	$57,862 $65.53 p/Share	883 Reduced 1.87%	46,387 Common Stock
Jan 29 2024	SELL Open market or private sale	$23,539 $64.14 p/Share	367 Reduced 0.77%	47,270 Common Stock
Jan 23 2024	SELL Open market or private sale	$272,975 $63.69 p/Share	4,286 Reduced 8.25%	47,637 Common Stock
Jan 22 2024	SELL Open market or private sale	$112,970 $65.0 p/Share	1,738 Reduced 3.24%	51,923 Common Stock
Jan 17 2024	SELL Open market or private sale	$214,840 $65.58 p/Share	3,276 Reduced 5.75%	53,661 Common Stock
Jan 16 2024	SELL Open market or private sale	$109,033 $66.81 p/Share	1,632 Reduced 2.79%	56,937 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	16,963 Added 22.46%	58,569 Common Stock
Jun 01 2023	SELL Open market or private sale	$430,000 $86.0 p/Share	5,000 Reduced 10.75%	41,504 Common Stock
Jun 01 2023	BUY Exercise of conversion of derivative security	$170,550 $34.11 p/Share	5,000 Added 9.71%	46,504 Common Stock
Apr 03 2023	SELL Open market or private sale	$375,000 $75.0 p/Share	5,000 Reduced 10.77%	41,430 Common Stock
Apr 03 2023	BUY Exercise of conversion of derivative security	$170,550 $34.11 p/Share	5,000 Added 9.72%	46,430 Common Stock
Feb 23 2023	SELL Open market or private sale	$75,911 $68.76 p/Share	1,104 Reduced 2.6%	41,430 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$32,350 $58.5 p/Share	553 Reduced 1.28%	42,534 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	6,628 Added 13.33%	43,087 Common Stock
Jan 30 2023	SELL Open market or private sale	$46,587 $52.76 p/Share	883 Reduced 2.36%	36,459 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$19,366 $52.77 p/Share	367 Reduced 0.97%	37,342 Common Stock
Jan 23 2023	SELL Open market or private sale	$152,418 $51.58 p/Share	2,955 Reduced 7.27%	37,709 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$73,442 $52.05 p/Share	1,411 Reduced 3.35%	40,664 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	19,634 Added 31.82%	42,075 Common Stock
Apr 25 2022	SELL Other acquisition or disposition	-	1,250 Reduced 5.33%	22,224 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$16,748 $38.59 p/Share	434 Reduced 1.82%	23,474 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	17,466 Added 42.21%	23,908 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	6,250 Added 50.0%	6,250 Common Stock

Karen Lewis

Chief People Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account